Randomized Phase II Trial of Chemoembolization and Sorafenib

NCT02908165 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped A future study will be taking place using the same patient population.

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: conventional TACE in combination with sorafenib, administered on a continuous schedule
DRUG: conventional TACE in combination with sorafenib, administered on a sequential schedule

Sponsor

Yale University